Soligenix (SNGX) Tax Provisions (2019 - 2023)

Soligenix's (SNGX) quarterly Tax Provisions came in at -$606606.0 in Q4 2023, up 47.76% on a QoQ basis from -$1.2 million in Q1 2023.

Soligenix (SNGX) Tax Provisions (2019 - 2023) Analysis & Trends

Soligenix (SNGX) has 5 years of Tax Provisions data on file, last reported at -$606606.0 in Q4 2023.

Quarterly Tax Provisions changed N/A year-over-year to -$606606.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$1.8 million (up 23.47% YoY) and the FY2025 annual result came in at -$506615.0, down 23.83% from the prior year.
Tax Provisions grew to -$606606.0 in Q4 2023, from -$1.2 million in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $836893.0 in Q4 2020 to a low of -$1.2 million in Q1 2023.
A 5-year average of -$713092.6 and a median of -$864742.0 in 2021 frame the typical range for Tax Provisions.
Annual changes were most pronounced in 2020 — Tax Provisions plunged 37.04% — and 2022, when it sank 33.56%.
Tracing SNGX's Tax Provisions over 5 years: stood at -$610676.0 in 2019, then surged by 237.04% to $836893.0 in 2020, then plunged by 203.33% to -$864742.0 in 2021, then tumbled by 33.56% to -$1.2 million in 2022, then surged by 47.48% to -$606606.0 in 2023.
The last three Tax Provisions figures came in at -$606606.0 (Q4 2023), -$1.2 million (Q1 2023), and -$1.2 million (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	59.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	15.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	75.45 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	13.31 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	1.90 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Soligenix	6.45 Mn	6.45 Mn	-	-

Download Data